Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

References

• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699.
   PubMed Web of Science ®Google Scholar
• Bergamasco A, Hartmann N, Wallace L, et al. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019;11:257–273.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76:1897–1905.
   PubMed Web of Science ®Google Scholar
• Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High-resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33:1789–1801.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518–2528.
   PubMed Web of Science ®Google Scholar
• Svetlana N, Denton C. Pathogenesis of systemic sclerosis associated interstitial lung disease. J Scleroderma Related Dis. 2020;5:6–16.
   Web of Science ®Google Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630–2640.
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77:212–220.
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. A randomized placebo-controlled phase 3 trial of tocilizumab in systemic sclerosis. Lancet Respir Med. 2020. In press.
   Google Scholar
• Shiwen X, Stratton R, Nikitorowicz-Buniak J, et al. A role of myocardin related transcription factor-A (MRTF-A) in scleroderma related fibrosis. PLoS One. 2015;10:e0126015.
   PubMed Web of Science ®Google Scholar
• Toyama T, Looney AP, Baker BM, et al. Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J Invest Dermatol. 2018;138:78–88.
   PubMed Web of Science ®Google Scholar
• Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54:1900161.
   PubMed Web of Science ®Google Scholar
• Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24:102–114.
   PubMed Web of Science ®Google Scholar
• Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc. 2006;3:377–382.
   PubMedGoogle Scholar
• Hung C, Linn G, Chow YH, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013;188:820–830.
   PubMed Web of Science ®Google Scholar
• Wollin L, Distler JHW, Denton CP, et al. Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease. J Scleroderma Related Dis. 2019;4:212–218.
   Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2666.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708–719.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 2017;69:1451–1460.
   PubMed Web of Science ®Google Scholar
• Roofeh D, Distler O, Allanore Y, et al. Treatment of systemic sclerosis associated ILD: lessons from clinical trials. J Scleroderma Related Dis. 2020;5(2S):61–70.
   PubMedGoogle Scholar
• Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57:2106–2113.
   PubMed Web of Science ®Google Scholar
• van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490–2498.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35–47.
   PubMed Web of Science ®Google Scholar
• Distler O, Volkmann ER, Hoffmann-Vold AM, et al. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol. 2019;15:1009–1017.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327–1339.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. J Respir Care Med. 2007;176:1026–1034.
   PubMed Web of Science ®Google Scholar
• Fernandez-Codina A, Walker KM, Pope JE, et al. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70:1820–1828.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts ling-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019;78:122–130.
   PubMed Web of Science ®Google Scholar
• Elhai M, Boubaya M, Distler O, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78:979–987.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367–373.
   PubMed Web of Science ®Google Scholar
• Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002;446:177–185.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011;22:1374–1381.
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769.
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016;43:1672–1679.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16:311–319.
   PubMed Web of Science ®Google Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.
   PubMed Web of Science ®Google Scholar
• Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349:209–220.
   PubMed Web of Science ®Google Scholar
• Tandon K, Herrmann F, Ayaub E, et al. Nintedanib attenuates the polarization of profibrotic macrophages through inhibition of tyrosine phosphorylation on CSF1 receptor. Am J Respir Crit Care Med. 2017;195:Abstract A2397.
   Web of Science ®Google Scholar
• Hilberg F, Tontsch-Grunt U, Baum A, et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J Pharmacol Exp Ther. 2018;364:494–503.
   PubMed Web of Science ®Google Scholar
• Sato S, Shinohara S, Hayashi S, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res. 2017;18:172.
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:157.
   PubMed Web of Science ®Google Scholar
• Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75:883–890.
   PubMed Web of Science ®Google Scholar
• Eferl R, Hasselblatt P, Rath M, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A. 2008;105:10525–10530.
   PubMed Web of Science ®Google Scholar
• Venalis P, Kum·novics G, Schulze-Koops H, et al. Cardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol. 2015;67:508–516.
   PubMed Web of Science ®Google Scholar
• Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76:1941–1948.
   PubMed Web of Science ®Google Scholar
• Dallinger C, Trommeshauser D, Marzin K, et al. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol. 2016;56:1387–1394.
   PubMed Web of Science ®Google Scholar
• Wind S, Schmid U, Freiwald M, et al. Clinical Pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019;58:1131–1147.
   PubMed Web of Science ®Google Scholar
• Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41:297–311.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Azuma A. Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease. Mod Rheumatol. 2019;20:1–7.
   Google Scholar
• Schmid U, Doege C, Dallinger C, et al. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2018;48:136–143.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–1755.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Kafaja S, Clements PJ, Wilhalme H, et al. Reliability and minimal clinically important differences of forced vital capacity: results from the scleroderma lung studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2018;197:644–652.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Khanna D, Volkmann E, et al. Improvement and stabilization of lung function in patients with SSc-ILD treated with nintedanib vs Placebo in a randomized placebo-controlled phase III trial: proportions of patients with FVC changes using cutoffs previously proposed to definite minimally clinically important differences.Arthritis Rheumatol. 2019;71(Suppl): 708.
   Web of Science ®Google Scholar
• Man A, Davidyock T, Ferguson LT, et al. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology (Oxford). 2015;54:1464–1471.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Shirai Y, Takeuchi T. elevated serum krebs von den lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol. 2016;43:1825–1831.
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–1815.
   PubMed Web of Science ®Google Scholar
• Khanna D, Mittoo S, Aggarwal R, et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group. J Rheumatol. 2015;42:2168–2171.
   PubMed Web of Science ®Google Scholar
• Highland K, Distler O, Kuwana M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: subgroup analysis of the SENSCIS trial. Arthritis Rheumatol. 2019;71(Suppl):1833.
   Google Scholar
• Distler O, Highland K, Mayes M, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial: subgroup analysis based on demographic characteristics. Arthritis Rheumatol. 2019;71(Suppl): 712
   Web of Science ®Google Scholar
• Kuwana M, Highland K, Gahlemann M, et al. Effects of nintedanib in patients with diffuse and limited cutaneous systemic sclerosis and interstitial lung disease: subgroup analysis of the SENSCIS trial. Arthritis Rheumatol. 2019;71(Suppl): 1644
   Google Scholar
• Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7:60–68.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Walscher J, Behr J. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Curr Opin Pulm Med. 2017;23:418–425.
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692.
   Web of Science ®Google Scholar
• Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076.
   Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–1727.
   PubMed Web of Science ®Google Scholar
• Noth I, Wijsenbeek M, Kolb M, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019;54:1801797.
   Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–1254.
   PubMed Web of Science ®Google Scholar
• Bezler RB, Lewis RJ. The practical significance of measurement error in pulmonary function testing conducted in research settings. Risk Anal. 2019;39:2316–2328.
   PubMed Web of Science ®Google Scholar
• Wu W, Jordan S, Graf N, et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European scleroderma trials and research (EUSTAR) cohort. Ann Rheum Dis. 2019;78:648–656.
   PubMed Web of Science ®Google Scholar
• Wu W, Jordan S, Becker MO, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis. 2018;77:1326–1332.
   PubMed Web of Science ®Google Scholar
• Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken). 2013;65:1375–1380.
   PubMed Web of Science ®Google Scholar
• Salazar GA, Kuwana M, Wu M, et al. KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease. J Rheumatol. 2018;45:1153–1158.
   PubMed Web of Science ®Google Scholar
• Markusse IM, Meijs J, de Boer B. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. Rheumatology (Oxford). 2017;56:1081–1088.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Distler O. Recent progress and missing gaps to achieve goal in the care of systemic sclerosis–associated interstitial lung disease. J Scleroderma Relt Disord. 2020;5(2S):3–5.
   Google Scholar
• Fernandez-Dias C, Loricera J, Castaneda S, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 oatients. Semin Arthritis Rheum. 2018;48:22–27.
   PubMed Web of Science ®Google Scholar
• Khanna D, Spino C, Johnson S, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2020;72:125–136.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Distler JHW. Therapeutic molecular targets of SSc-ILD. J Scleroderma Relt Disord. 2020;5(2S):17–30.
   Google Scholar
• Hoffmann-Vold AM, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020;2:71–83.
   Google Scholar